Zika is on the Agenda at the 17th ICID

Dengue, Chikungunya and Zika Virus Go Global, a Symposium organized in collaboration with the Brazilian Society of Infectious Diseases

Zika, MERS, Ebola, SARS and H1N1: Local and Global Responses to Viral Threats, Paul Tambyah, Plenary Lecture

Zika Virus Neurological Associations, Tom Solomon, in the Symposium: Infectious Encephalitis: Advances and Unknown

WHO Reforms and UN Actions, Dan Lucey, in the Symposium: Preparing for the Next Pandemic

Organized by the International Society for Infectious Diseases
17th ICID - WEDNESDAY MARCH 2

SCIENTIFIC PROGRAM

PRE-Congress Workshops
(Attendance is limited to ICID Registrants)

Antibiotic Stewardship in the Resource Limited Setting
(in collaboration with the British Society for Antimicrobial Chemotherapy)
13:00 - 17:00hrs - NO FEE - Limited capacity

Innovative Strategies in Hand Hygiene Promotion Around the World
14:00 - 16:30hrs - NO FEE - Limited capacity

Building Capacity for Infectious Disease Outbreak Investigations (OIs) - Increasing the Quality and Quantity of OIs for Field Epidemiology Residents (organized by the South African Field Epidemiology Training Programme)

17th ICID - THURSDAY MARCH 3

SCIENTIFIC PROGRAM

MEET-THE-EXPERT
Clinical Case Discussions for Trainees
Thursday, March 3, 2016, 07:45 - 08:45hrs
V. Gant (UK)

The Value of Adult Vaccination
Thursday, March 3, 2016, 07:45 - 08:45hrs
J. Litt (Australia) Herpes Zoster Management
D. Fedson (France) Pneumococcal Disease in Adults

PLENARY I
Streptococcal Lymphatic Metastasis: Bacterial Close Encounters of the Fourth Kind
Thursday, March 3, 2016, 09:00 - 09:45hrs
S. Sriskandan (UK)

PARALLEL SYMPOSIA
Prevention of Childhood Pneumonia Through Vaccination
(in collaboration with the Bill & Melinda Gates Foundation)
Thursday, March 3, 2016, 10:15 - 12:15hrs

- Global Burden of Pneumococcal Pneumonia
K. Thomas (India)

- Pneumonia in India
S. Awasthi (India)

- Prevention of Pneumonia
R. Dagan (Israel)

- The Path to Pneumonia Prevention in India - Call to Action
R. Kumar (India)

Potential Role of Dengue Vaccination in Integrated Disease Prevention and Control (Symposium developed in collaboration with and supported by an

Congress website: http://www.isid.org./icid/
Register online
Follow the 17th ICID on Facebook
Twitter: #17th ICID
The Burden of Dengue: Insights from Large Scale Clinical Studies
O. Brady (UK)

Recent Update on Dengue Vaccine Development
P. Pitisuttithum (Thailand)

Dengue Vaccination Impact: Perspective from Modeling
T. Hladish (USA)

Roadmap for Dengue Vaccination Introduction to Mexico
M. Betancourt (Mexico)

Diagnosis and Treatment of Carbapenem-resistant Enterobacteriaceae (in collaboration with the Japanese Association for Infectious Diseases)
Thursday, March 3, 2016, 10:15 - 12:15hrs

Molecular Diagnosis of Carbapenem-resistant Enterobacteriaceae
Y. Ishii (Japan)

Detection of Resistant Enterobacteriaceae in Clinical Isolates
TBD

Controlling Carbapenem-resistant Enterobacteriaceae in your Hospital
L. Munoz-Price (USA)

Appropriate Therapy for Carbapenem-resistant Enterobacteriaceae
O. Abraham (India)

Antifungal Prophylaxis or Treatment - Why, When & What (symposium developed in collaboration with and supported by an educational grant from MSD)
Thursday, March 3, 2016, 10:15 - 12:15hrs, Room: Hall 6

Making Clinical Sense of Candida & Aspergillus Susceptibilities
N. Weiderhold (USA)

Why Prophylaxis for IFI
A. Pagliuca (UK)

Risk Stratification for Treatment or Prophylaxis of Invasive Fungal Infections
M. Slavin (Australia)

New Options for Prevention & Treatment of IFI
R. Duarte (Spain)

HIV - Management of Opportunistic Infections in Low-and-Middle-Income Countries
Thursday, March 3, 2016, 10:15 - 12:15hrs

HIV/TB Co-infection
S. Swaminathan (India)

Cryptococcal Meningitis and Beyond - Management of Select Opportunistic Infections in Sub-Saharan Africa
G. Meintjes (South Africa)

Challenges in the Management of Opportunistic Infections: Focus on South East Asia
A. Kamarulzaman (Malaysia)

Challenges in the Management of Opportunistic infections: Focus on South America
J. Torres (Venezuela)

One Health and Emerging Infectious Diseases
Thursday, March 3, 2016, 10:15 - 12:15hrs

Mers-CoV: from Camels to Humans
Z. Memish (Saudi Arabia)

Climate Change and Other Drivers of Infectious Diseases - Focus on the Global South
J. Torres (Venezuela)
PLENARY II
Challenges and Opportunities in the Management of Chronic Hepatitis B Infection
Thursday, March 3, 2016, 14:30 - 15:15hrs
C.L. Lai (China)

PARALLEL SYMPOSIA
Antibiotic Resistance: National Actions Contribute to a Global Solution (in collaboration with the Center for Disease Dynamics, Economics & Policy)
Thursday, March 3, 2016, 15:45 - 17:45hrs

- India Perspective on Antibiotic Resistance
- South Africa Perspective on Antibiotic Resistance
  M. Mendelson (South Africa)
- Kenya Perspective on Antibiotic Resistance
  C. Mailu and G. Revathi (Kenya)
- Nepal Perspective on Antibiotic Resistance
  P. Pokharel (Nepal)
- Mozambique Perspective on Antibiotic Resistance
  N. Abdula and B. Sigauque (Mozambique)
- Lessons Learned
  H. Gellband (USA)
- Panel Discussion
  R. Laxminarayan (India)

Ebola and Beyond: Preparing for the Next Pandemic
Thursday, March 3, 2016, 15:45 - 17:45hrs

- India - National Disaster and Epidemic Preparedness
  V. Menon (India)
- Influenza Preparedness Including H1N1
  M. Chadha (India)
- Conducting Clinical Trials in the Outbreak Setting - MSF’s Perspective
  H. de Clerck (Belgium)
- WHO Reforms and UN Actions
  D. Lucey (USA)

Advances and Understanding in the Management of Drug Resistant Tuberculosis (a member proposed symposium)
Thursday, March 3, 2016, 15:45 - 17:45hrs

- Multidrug Resistant TB in Children: Special Considerations
  F. Qamar (Pakistan)
- Diagnostic Advances in Assessing Drug Resistant TB
  C. Rodrigues (India)
- Translating Genomics Research into Control of MDR Tuberculosis: Lessons Learned and Future Prospects
  M. Nicol (South Africa)
- Treatment Options for MDR TB and Host Directed Therapies
  R. Wallis (USA)

Malaria - Hot Topics
Thursday, March 3, 2016, 15:45 - 17:45hrs

- The Threat of Antimalarial Drug Resistance
  E. Ashley (UK)
- Treatment of Drug Resistant Malaria
MEET-THE-EXPERT
Strengthening Disease Surveillance, Emergency Preparedness and Risk Communication for Health Security in India (in collaboration with the International Society for Disease Surveillance (ISDS)
Friday, March 4, 2016, 07:45 - 08:45hrs
V. Singh (India) and P. Murthy (India)

PLENARY III
Malaria: Past, Present and Future
Friday, March 4, 2016, 09:00 - 09:45hrs
N. White (Thailand)

PARALLEL SYMPOSIA
Infectious Encephalitis: Advances and Unknown (in collaboration with the Lancet Infectious Diseases)
Friday, March 4, 2016, 10:15 - 12:15hrs

- Flavivirus Encephalitis (Zika, Dengue, JE, WNV, TBE)
  T. Solomon (United Kingdom)
- Enterovirus Encephalitis Including Enterovirus 71 and D68
  TBD
- Acute Encephalitis Syndrome of Unknown Etiology
  R. Vasanthapuram (India)
- Rabies Encephalitis
  A. Jackson (Canada)

The Future of Infectious Diseases Diagnostics (in collaboration with the Indian Association of Medical Microbiologists)
Friday, March 4, 2016, 10:15 - 12:15hrs

- Maldi-TOF
  A. Chakrabarti (India)
- Microbial Culturomics
  D. Raoult (France)
- Point of Care Testing for Global Health
  V. Gant (United Kingdom)
- Whole Genome Sequencing in Diagnostic Microbiology
T. Peto (UK)

Childhood Vaccinations: The Old and the New  
*in collaboration with the Indian Academy of Pediatrics*  
Friday, March 4, 2016, 10:15 - 12:15hrs

- Polio: The Endgame Strategy  
  J. John (India)  
- Hib Vaccine: A Looming Success  
  R. Hajjeh (USA)  
- Pneumococcal Conjugate Vaccines  
  S. Saha (Bangladesh)  
- Measles Eradication  
  TBD

Managing the Most Problematic Gram Negative Bacterial Infections  
*developed in collaboration with and supported by an educational grant from MSD*  
Friday, March 4, 2016, 10:15 - 12:15hrs, Room: Hall 6

- Antibiotic Use & Global Trends of Gram Negative Resistance  
  C. Rodrigues (India)  
- Risk Stratification: Identifying the Right Patient  
  M. Bassetti (Italy)  
- Strategic Options for Management of GNB Infections  
  A. Shorr (USA)  
- Role of Antimicrobial Stewardship & Strategies for Appropriate Therapy  
  G. Karam (USA)

Melioidosis: A South Asian Disease Emerging Globally *(a member proposed symposium)*  
Friday, March 4, 2016, 10:15 - 12:15hrs

- Melioidosis Endemicity in India  
  C. Mukhopadhyay (India)  
- Predicted Distribution of B. pseudomallei and Burden of Melioidosis in South Asia and Worldwide  
  D. Limmathurotsakul (Thailand)  
- Why is Melioidosis Difficult to Treat? - Insights into Pathogenesis  
  J. Wiersinga (Netherlands)  
- Challenges in Diagnosis and Management of Melioidosis  
  D. Dance (UK)

Oral Abstract Presentations (2)  
Friday, March 4, 2016, 10:15 - 12:15hrs

PLENARY IV

Tuberculosis: Challenges and Solutions for the 21st Century  
Friday, March 4, 2016, 14:30 - 15:15hrs  
S. Swaminathan (India)

PARALLEL SYMPOSIA

Intestinal Microbiota in Health and Disease  
Friday, March 4, 2016, 15:45 - 17:45hrs

- The Healthy Human Antibiotic Resistome: A Multi-body Habitat Analysis  
  M. Mitreva (USA)  
- The Role of the Neonatal Microbiome in Health and Disease  
  P. Panigrahi (USA)  
- Fecal Microbiota Transplants - The Clinical Perspective  
  I. Youngster (USA)  
- Beneficial Modification of Gut Microbiota  
  P. Cotter (Ireland)
Pediatric Diarrhea in Low Income Countries: Rotavirus and Beyond
Friday, March 4, 2016, 15:45 - 17:45hrs

- Rotavirus Vaccines - A Promise Kept
  J. Tate (USA)
- Norovirus Infection and Vaccine Development: Where are we?
  M. O’Ryan (Chile)
- The Outcomes of Cryptosporidial Infections in Indian Children
  G. Kang (India)
- Molecular Diagnostics and the Aetiology of Diarrhea in Low-income Countries
  J. Platts-Mills (USA)

Dengue, Chikungunya and Zika Virus Go Global
(in collaboration with the Brazilian Society of Infectious Diseases)
Friday, March 4, 2016, 15:45 - 17:45hrs

- Dengue, Chikungunya and Zika Virus: Global Emergence
  K. Luz (Brazil)
- Pathogenesis of Severe Dengue
  N. Malavige (Sri Lanka)
- Management of Severe Dengue
  Y. S Leo (Singapore)
- Zika Virus, What you Need to Know
  T. Yuill (USA), R. Hajjeh (USA), K. Luz (Brazil)

Neglected Infectious Diseases Around the World (in collaboration with the Clinical Infectious Diseases Society of India)
Friday, March 4, 2016, 15:45 - 17:45hrs

- Leptospirosis
  D. Diament (Brazil)
- Leprosy
  J. Muliyl (India)
- Parasitic Infections and Allergies
  P. Cooper (Ecuador)
- Infectious Disease Pathology in India: Interactive Cases
  R. Gopalakrishnan (India)

The Silent Epidemic of Hepatitis
Friday, March 4, 2016, 15:45 - 17:45hrs

- Hepatitis C Infection in People who Inject Drugs
  T. Azim (Bangladesh)
- HCV State of the Art: Who, When and How to Treat
  J. Koirala (USA)
- HIV and Viral Hepatitis Co-infection
  G. Matthews (Australia)
- Hepatitis E Vaccine - Where are we Today?
  P. Abraham (India)

Oral Abstract Presentations (3)
Friday, March 4, 2016, 15:45 - 17:45hrs

17th ICID - SATURDAY MARCH 5

SCIENTIFIC PROGRAM

MEET-THE-EXPERT
Clinical Cases in Tropical Dermatology
Saturday, March 5, 2016, 07:45 - 08:45hrs
A. Sethi (USA)
Clinical Management of Anti-fungal Resistance - Interactive Cases
Saturday, March 5, 2016, 07:45 - 08:45hrs
F. Menichetti (Italy)

PLENARY V
Antimicrobial Resistance: From Problem to Policy to Action
Saturday, March 5, 2016, 09:00 - 09:45hrs
S. Davies (UK)

PARALLEL SYMPOSIA
Infections in the Era of Cancer Treatments, Transplants and New Biologics
(in collaboration with the Clinical Infectious Diseases Society India and the European Society of Clinical Microbiology and Infectious Diseases)
Saturday, March 5, 2016, 10:15 - 12:15hrs

- Fungal Infections in Stem Cell Transplants
  S. Swaminathan (India)
- Neutropenic Sepsis
  F. Menichetti (Italy)
- Infections in the Era of New Biologics
  S. Opal (USA)
- CMV
  P. Ljungman (Sweden)

New and Recently Approved Antibiotics: Challenges and Opportunities
(in collaboration with DRIVE-AB- a project of the Innovative Medicines Initiative)
Saturday, March 5, 2016, 10:15 - 12:15hrs

- New Antibiotics: What do we Need?
  D. Morgan (USA)
- The Antibiotic Pipeline: What Can we Expect?
  U. Theuretzbacher (Austria)
- Incentivizing Antibiotic Innovation
  C. Årdal (Norway)
- Sustaining the Clinical Use of Antibiotics
  A. Holmes (United Kingdom)

HIV - Hot Topics in Antiretroviral Therapy and its Consequences
Saturday, March 5, 2016, 10:15 - 12:15hrs

- HIV Prevention
  K. Mayer (USA)
- The Good, the Bad and the Beautiful: Anti-retroviral Therapy Considerations in Children and Adolescents
  A. Shet (India)
- Manifestations and Management of IRIS
  G. Meintjes (South Africa)
- Impact of Antiretroviral Resistance on Future Treatment Options in Resource Limited Settings
  N. Kumarasamy (India)

Update on Visceral Leishmaniasis in South Asia
(in collaboration with the Drugs for Neglected Diseases initiative)
Saturday, March 5, 2016, 10:15 - 12:15hrs

- Active Case Finding of Kala-azar
  P. Das (India)
- Update on Treatment of Kala-azar
  S. Sundar (India)
- Post-kala-azar Dermal Leishmaniasis: Burden, Diagnosis and Treatment Challenges
  V. Ramesh (India)
- Management of HIV Visceral Leishmaniasis Co-infection
  S. Burza (UK)
Infectious Diseases in Refugees, Migrants and Internally Displaced Persons
(supported in part with a North Atlantic Treaty Organization grant)
Saturday, March 5, 2016, 10:15 - 12:15hrs

- Screening of Migrants Through the Mediterranean Sea to Europe
  R. Cauda (Italy)
- Managing Health and Infections in Refugees: Turkey's Experience
  H. Leblebicioglu (Turkey)
- Rapid Diagnostic Point of Care Tests in Resource Limited Settings
  J. Kafkova (Kenya)
- Common Infections in Internally Displaced after Military Operations in North Iraq
  V. Krcmery (Slovakia)

Oral Abstract Presentations (4)
Saturday, March 5, 2016, 10:15 - 12:15hrs

PLENARY VI
Zika, MERS, Ebola, SARS and H1N1: Local and Global Responses to Viral Threats
Saturday, March 5, 2016, 14:30 - 15:15hrs
P. Tambyah (Singapore)

PARALLEL SYMPOSIA
Sepsis and Other Infections in Critical Care
(in collaboration with the Clinical Infectious Diseases Society India)
Saturday, March 5, 2016, 15:45 - 17:45hrs

- Intensive Care Considerations in Epidemics
  P. Tambyah (Singapore)
- Epidemiology of Sepsis in Low and Middle Income Countries
  V. Ramasubramanian (India)
- Antibiotic Use in the ICU - MDR Organisms
  TBD
- New Therapeutics
  S. Opal (USA)

Enteric Fever Prevention and Control Strategies
Saturday, March 5, 2016, 15:45 - 17:45hrs

- Disease Burden of Typhoid Fever: Updates from the SEAP Project
  D. Garrett (USA)
- Development Status of Typhoid Conjugate Vaccines Globally
  S. Sahastrabuddhe (Republic of Korea)
- Strategies on Containing and Treating Drug Resistant Typhoid in Low and Middle Income Countries
  A. Arjyal (Nepal)
- Typhoid Global Policy Recommendations
  A. Zaidi (USA)

Protecting the Healthcare Worker Around the World
Saturday, March 5, 2016, 15:45 - 17:45hrs

- Protecting the Healthcare Worker Around the World
  R. Gallagher (UK)
- Technologies for Hospital Disinfection and Textiles for Bioburden Reduction
  G. Bearman (USA)
- The Impact of Education on Reducing Ebola Virus Disease Transmission in Healthcare Facilities
  S. Mehtar (South Africa)
- Protecting the Healthcare Worker During Outbreaks - Médecins sans Frontières

sans Frontieres Perspective
H. de Clerck (Belgium)

Sexually Transmitted Infections: Global Challenges
Saturday, March 5, 2016, 15:45 - 17:45hrs

- HIV and Syphilis
  K. Mayer (USA)
- Prostatitis: Challenges in Diagnosis and Treatment
  K. Naber (Germany)
- Global Challenges of Implementing Human Papillomavirus Vaccines
  H. Rees (South Africa)
- Prospects of Untreatable Gonorrhea and Ways Forward
  TBD

The ICID Program is subject to change. Please visit the Congress website for updates.

17th ICID
Sponsors, Contributors and Participating Organizations

The organizers of the 17th ICID wish to gratefully acknowledge our Sponsors, Contributors, and Participating Organizations

17th ICID PREMIER SPONSORS

17th ICID SPONSORS

17th ICID OFFICIAL AIRLINE

17th ICID CO-OPERATING ORGANIZATIONS

British Society for Antimicrobial Chemotherapy
Center for Disease Dynamics, Economics & Policy
Clinical Infectious Disease Society (CIDS)
Department of Biotechnology
SHIRANEE SRISKANDAN
‘Streptococcal Lymphatic Metastasis: Bacterial Close Encounters of the Fourth Kind’
Shiranee Sriskandan is Professor of Infectious Diseases at Imperial College London and an Infectious Diseases clinical consultant. She leads the Gram Positive Pathogenesis research group, in addition to the molecular bacteriology work of the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, in partnership with Public Health England, and Imperial’s Biomedical Research Centre. Her research group addresses the mechanisms by which Streptococcus pyogenes causes extreme clinical phenotypes in individuals and populations, examining the interface between pathogen molecular microbiology and host immune response.

SALLY Y C. DAVIES
‘Antimicrobial Resistance: From Problem to Policy to Action’
Professor Dame Sally Davies is England's Chief Medical Officer (CMO), and the Chief Scientific Adviser for the Department of Health. As CMO she is the independent advisor to the Government on all medical matters, particularly Public Health. The CMO also advises the Health Secretary on medical matters and promoting the health and well being of the people of England. She carries the rank of Permanent Secretary and is the professional head of the Department’s medical staff and head of the Medical Civil Service. Prof. Davies has been actively involved in NHS R&D from its establishment. As Director-General she established the National Institute for Health Research (NIHR) with a budget of £1 billion. Her own research interests focused on Sickle Cell disease.

CHING-LUNG LAI
‘Challenges and Opportunities in the Management of Chronic Hepatitis B Infection’
Ching-Lung Lai is the Simon K Y Lee Professor in Gastroenterology and the Chair Professor of Medicine and Hepatology at the Department of Medicine, University of Hong Kong, where he has been working since his graduation.

For the last three decades he has been extensively
involved in research into various aspects of HBV, including hepatocellular carcinoma. He is one of the lead investigators in the pivotal trials of various nucleos(t)ide analogues which have revolutionised the treatment of chronic hepatitis B. He and his colleagues have also been investigating the still emerging field of the natural history of chronic hepatitis B, with findings which have an important bearing on the treatment end-points for chronic hepatitis B.

SOUMYA SWAMINATHAN
‘Tuberculosis: Challenges and Solutions in the 21st Century’

Dr. Swaminathan is a pediatrician by training, having completed her medical education at the Armed Forces Medical College and the All India Institute of Medical Sciences followed by a fellowship in pediatric pulmonology at the Children’s Hospital of Los Angeles. She has spent over 24 years at the Tuberculosis Research Centre in Chennai, (now renamed the National Institute for Research in Tuberculosis), where she is currently the Director. She has over 200 peer-reviewed publications and serves on many national and international committees. Her major research interests are in pediatric and adult TB, their interaction with HIV and nutrition and the management of co-infections as well as pharmacokinetics and pharmacogenetics.

Dr. Swaminathan was appointed as Director General of the Indian Council of Medical Research (ICMR) and Secretary, Department of Health Research (Ministry of Health & Family Welfare) in August 2015. She will head a network of 32 research centres under ICMR, the apex body for coordination and promotion of biomedical research in India.

PAUL ANANTHARAJAH TAMBYAH
‘Zika, MERS, Ebola, SARS and H1N1: Local and Global Responses to Viral Threats’

Paul Anantharajah Tambyah is currently Professor of Medicine at the National University of Singapore and Senior Consultant Infectious Diseases Physician at the National University Hospital. He is also Research Director in the Division of Infectious Diseases of the National University Health System. After graduating from the National University of Singapore, he did his postgraduate training at the University of Wisconsin under Dr Dennis Maki and since returning to Singapore in 1999 he has held a number of academic, professional and advisory appointments including Assistant Dean of the Yong Loo Lin School of Medicine. He is immediate past President of the Society of Infectious Diseases (Singapore) and Secretary-General of the Asia Pacific Society of Clinical Microbiology and Infection.

NICHOLAS JOHN WHITE
‘Malaria: Past, Present and Future’ [Ronald Ross Memorial Plenary Lecture]

Nick White, Professor of Tropical Medicine at the Faculty of Tropical Medicine, Mahidol University, Thailand and at Oxford University, UK, and Consultant Physician at the John Radcliffe Hospital, Oxford, is a Wellcome Trust Principal Research Fellow who chairs the Wellcome Trust Tropical Medicine Research Programmes in South East Asia. He trained in medicine in London at Guy’s Hospital and he has lived and worked in Thailand since 1980. His
research focus is the pathophysiology and treatment of malaria. He has concentrated on characterising antimalarial pharmacokinetic-pharmacodynamic relationships to improve the treatment of malaria and to reduce the emergence of resistance. This led to artemisinin based combination treatment for falciparum malaria, and the change to artesunate for the treatment of severe malaria. He currently chairs the WorldWide Antimalarial Resistance Network and he co-chairs the WHO Global Malaria Programme technical expert group on the prevention and treatment of malaria, and the WHO antimalarial treatment guidelines committee.

2016 International Meeting on Emerging Diseases and Surveillance

SAVE THE DATE!
November 4-7, 2016
Vienna, Austria

Topics: Planned session topics include:

- Disease Surveillance, Detection, Reporting and Outbreak Modeling
- Ethics of new methodologies of disease surveillance
- Vectorborne and Zoonotic Diseases
- Foodborne and Waterborne Infections
- Infections Related to Travel and Migration of Humans and Animals
- Animal Reservoirs for Emerging Pathogens
- Agents of Bioterrorism/Biological Warfare
- Laboratory Biosafety and Emerging Pathogen Research
- Specific Disease Threats: Pandemic Influenza, Anthrax, C. difficile, Q fever, Rift Valley Fever, MERS, West Nile Virus, Zika Virus, Hemorrhagic Fevers, Bluetongue, Chikungunya, TSEs, Healthcare Associated Infections, and Others.
- Antimicrobial Resistance
- Vaccines and Diagnostics for Emerging Diseases
- Submitted Abstracts (Oral and Poster)

Updates: [http://imed.isid.org/](http://imed.isid.org/)

**Abstract submission:** The deadline for abstract submission - July 2016.
Dalichi Sankyo India Pharma Private Limited

Dalichi Sankyo India Pharma Private Limited (DSII) is an organization working in the field of innovative pharmaceutical Research & Development (R&D) in India. DSII was established in 2007 and has given a great contribution to global R&D in Dalichi Sankyo Group, which has a history of more than 150 years. Our aim is to create first-in-class and best-in-class drugs which meet medical needs around the world.

Dalichi Sankyo Life Sciences Research Centre in India (RCI) is the research division of DSII. RCI focuses on small molecule drug discovery research in the areas of infectious and autoimmune diseases. RCI is equipped with state-of-the-art laboratories for the design, synthesis and evaluation of new chemical entities for biological activity and drug-like characteristics using in vitro and in vivo experimental evaluation.

RCI is open to collaborations with academic institutes, scientific societies and government organizations. Such collaborations contribute not only towards the identification of novel biological pathways and novel chemical scaffolds, but also provide several opportunities for mutual learning and knowledge sharing.

Dalichi Sankyo India Development (DSID) is the development division of DSII. DSID focuses on global clinical trials conducted by Dalichi Sankyo and provides critical supervision to the clinical trials done in India. DSID’s focus area are interlinked with Dalichi Sankyo’s global pipeline - Oncology, Cardiovascular diseases, Frontier opportunities (Metabolism and Infectious Diseases) as also Early Clinical Development.

At DSID, we oversee the India part of the global clinical trials and also endeavor to conduct studies for the local India and Asia specific indications.

Corporate Office and R&D Center:
Village Sahaul, Sector-18, Udarghat Industrial Area
Gurgaon, Haryana-122 015, India
GSTR No.: U24223KG2017PTC043682
www.dspi.co.in
Pneumococcal Disease Prevention: Further Evidence of Success
Friday, March 4, 2016
12:30 – 2:00 PM
Hall 6

AGENDA
12:30 – 1:00 pm
Remarks by Chair
Mark A. Fletcher, MD
Park, Nimmo

PCV Protection of Children: A Story of Immune Response, Serotype by Serotype
1:05 – 1:15 pm
Helping to Protect Against Pneumococcal Disease Across Generations: Public Health Impact of PCVs
Nick Singh, MD
PD Hinduja Hospital for Children
3B, Wadia Hospital, Lilavati Hospital
Mumbai, India

Pneumococcal Vaccination in Older Adults: Where Is the Evidence Leading?
1:15 – 1:25 pm
The Burden of Pneumococcal Pneumonia in Adult Populations: Recognizing an Unmet Need
Ruanne Philipson, MD
Santa Clara Hospital and Maternity
Per/Path Panorama
São Paulo, Brazil
1:25 – 1:35 pm
Helping to Protect Adults Against Pneumococcal Pneumonia: From Clinical Trials to Vaccine Policy
Charles, Feldman, MB BS, BSc., PhD, FPCE, FCP FSAL
Charlotte Maxeke, Johannesburg Academic Hospital
University of the Witwatersrand
Johannesburg, South Africa
1:35 – 2:00 pm
Summary and Concluding Remarks
Mark A. Fletcher, MD
Park, Nimmo

For the use of a registered medical practitioner, Hospital for laboratory.
For additional information, prior written approval.
Pfizer: United, The Capitol - 4 Wing 10th Floor,
Plot No C-70, G-Block, Sanara - Kothi Colony,
Banera (Booth, Mumbai - 400002), India.
PP: PM-ILR-0010
31/07/2016
Following the successes of vaccination in the 20th Century, we need to be more than ever prepared to support and convey the value of vaccination against measles, mumps, rubella, varicella and pertussis in certain age groups. During recent years there has been a series of outbreaks of pertussis, measles and mumps, mainly due to insufficient vaccine and booster vaccine coverage. The symposium “Pertussis, The prevention starts with you” will be chaired by Dr Sundaram Balasubramanian, Head of the Department of Pediatrics at Kanchi Kamakoti CHILDS Trust Hospital and Medical Research Foundation, Chennai, India. During a round table discussion the faculty, composed of the GSK experts Dr Linda Hanssens, Global Medical Affairs Lead for DTP combination vaccines, Dr Anil Dutta, Vice-President & Head, Medical and Clinical – Emerging Markets, and Dr Tomas Manek, Senior Manager Global Medical Affairs for DTP combination vaccines, will address from a global and regional perspective the epidemiology of pertussis, discuss experiences with strategies adopted for optimising pertussis control, as well as recently published data and unmet medical needs.

The GSK symposium “Do MMRV combination vaccines optimise the prevention of measles, mumps, rubella and varicella?” is designed to tackle some of the burning questions on Measles, Mumps, Rubella and Varicella combination vaccines. Lessons learned all over the world with different MMRV vaccination schedules will be discussed as well as the safety aspects of combination vaccines. New Indian data will be presented with the use of MMRV vaccine for the first time in a highly endemic measles setting. The expert faculty consisting of Dr Sanjay Latwani, Department of Pediatrics, Bharati Vidyapeeth Deemed University, Pune, India, Dr Anil Dutta GSK, Vice-President & Head, Medical and Clinical - Emerging Markets, and Dr Volkert Vetter, GSK Global Medical Affairs Lead for MMRV vaccines will openly discuss different viewpoints.

Upgrade your knowledge on vaccines from the observations, insights and experiences of our expert speakers.

References

Date of preparation: January 2016  VSEL0013511dia
Geevirthiiline Pharmaceuticals Limited, Dr. Annie Besant Road, Worli, Mumbai 400 030 (India).
Please report adverse events with any GSK product to the company at india.pharmavigilance@gsk.com
© 2016 by GSK Biological. All rights reserved.
Follow us on Facebook

**ISID on Facebook**

Another way to keep up to date with ISID, the 17th ICID and the International Meeting on Emerging Diseases and Surveillance.

If you wish to modify your membership status at ISID please contact the Society at [membership@isid.org](mailto:membership@isid.org)